Invida buys in Indonesia to gain local production presence

By Nick Taylor

- Last updated on GMT

Related tags Indonesia Marketing

Invida has acquired a stake in Indonesia-based MUGI, giving it the local manufacturing presence needed to offer partners access to “a vast untapped market”.

Operating a local manufacturing facility allows Invida to hold product licenses in Indonesia on behalf of its partners. This removes the needs for foreign companies to establish their own production sites, providing an alternative way of entering the Indonesia market.

Expanding operations into Indonesia “strongly improves our chance to secure new business​” by opening up a new market, John Graham, CEO of Invida, told in-PharmaTechnologist.

Graham added that Indonesia is a “vast untapped market​” where growth is being driven by the region’s​“burgeoning economic landscape, rising affluence and increased healthcare demand​”.

Companies looking to enter this market can now use Invida to procure product licenses and obtain regulatory approvals. Invida is also offering manufacturing, sales and marketing services.

With the acquisition of MUGI, Invida also further cements its role as a single point of entry for those companies looking for a strategic partner to access Asia Pacific markets​”, commented Graham in a press statement.

To gain these capabilities Invida has acquired a 70 per cent stake in Indonesia-based MUGI. Financial details of the deal have not been disclosed.

Local manufacturing

MUGI operates a production facility in Indonesia where it manufactures dermatological, liquid and oral solid-dose formulations. Invida has stated the site will “undergo a major upgrade​” to make it compliant with current good manufacturing practices (cGMP).

This will allow MUGI to offer manufacturing services for a wide range of products, either for local use or export. Invida believes providing manufacturing services for both local and foreign companies could be a significant long-term opportunity for the company and its partners.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

A Guide Through the API Drug Development Pipeline

A Guide Through the API Drug Development Pipeline

Content provided by Lonza Small Molecules | 11-Jul-2023 | Insight Guide

With the complexities associated with API and HPAPI drug development, it’s necessary to lean on the experts. With Q&A sections, insights and articles...

Related suppliers

Follow us


View more